Ergoteles’s Tango Therapeutics TNGX Stock Holding History

Ergoteles’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-15,372	Closed	-$60.7K	–	1531
2023 Q1	$60.7K	Buy	+15,372	New	+$89.2K	﹤0.01%	1127

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ergoteles's TNGX Position: Q2 2023 in Review

Ergoteles sold out of Tango Therapeutics (TNGX) in Q2 2023, closing a stake of 15,372 shares — an estimated $60.7K sold.

Ergoteles first reported a position in TNGX in Q1 2023 and held it in 1 quarter. The position peaked at $60.7K in Q1 2023. 89 funds tracked by Wall St. Rank hold TNGX as of Q2 2023.

Ergoteles reported no remaining Tango Therapeutics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 15,372 Tango Therapeutics shares in Q2 2023, an estimated $60.7K.
Ergoteles first reported a position in Tango Therapeutics in Q1 2023 and held it in 1 quarter.
Ergoteles's Tango Therapeutics position peaked at $60.7K in Q1 2023.
89 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.